Q2 2025 Earnings Estimate for Jazz Pharmaceuticals plc Issued By Zacks Research (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – Analysts at Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for shares of Jazz Pharmaceuticals in a research report issued to clients and investors on Monday, October 14th. Zacks Research analyst S. Ganoria now anticipates that the specialty pharmaceutical company will post earnings of $4.09 per share for the quarter, up from their prior forecast of $4.08. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.03 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q3 2025 earnings at $4.35 EPS, FY2025 earnings at $16.12 EPS, Q1 2026 earnings at $3.77 EPS, Q2 2026 earnings at $4.33 EPS and Q3 2026 earnings at $4.67 EPS.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion.

JAZZ has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Robert W. Baird lowered their price target on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a report on Thursday, August 1st. UBS Group lowered their price target on Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a report on Tuesday, July 2nd. Royal Bank of Canada increased their price target on Jazz Pharmaceuticals from $174.00 to $175.00 and gave the company an “outperform” rating in a report on Friday, October 4th. Finally, JPMorgan Chase & Co. increased their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a report on Monday, August 19th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $173.14.

Jazz Pharmaceuticals Stock Performance

JAZZ stock opened at $115.65 on Tuesday. The stock has a market capitalization of $7.29 billion, a PE ratio of 23.85, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $137.38. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The stock’s 50 day simple moving average is $110.78 and its 200 day simple moving average is $109.78.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently bought and sold shares of JAZZ. EverSource Wealth Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Jazz Pharmaceuticals by 0.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 16,082 shares of the specialty pharmaceutical company’s stock worth $1,937,000 after acquiring an additional 99 shares in the last quarter. ProShare Advisors LLC grew its position in Jazz Pharmaceuticals by 1.4% in the first quarter. ProShare Advisors LLC now owns 7,439 shares of the specialty pharmaceutical company’s stock worth $896,000 after acquiring an additional 105 shares in the last quarter. GAMMA Investing LLC grew its position in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 116 shares in the last quarter. Finally, Platinum Investment Management Ltd. grew its position in Jazz Pharmaceuticals by 17.8% in the first quarter. Platinum Investment Management Ltd. now owns 821 shares of the specialty pharmaceutical company’s stock worth $99,000 after acquiring an additional 124 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.